Speakers

Expand/Collapse

Irena Adkins
Lead Scientist Pharmacology
SOTIO

Day One

Thursday 13th December 2018

9:10 am | Understanding the Mechanistic Actions & Development of IL-15Rβγ Agonist

Aaron Cranston
Head of Translational Research
Almac Discovery Ltd., Belfast, United Kingdom

Day Two

Thursday 13th December 2018

1:40 pm | What’s in Our Translational Science Toolbox? Preclinical Oncology Model Selection in the Genomic Era – A Biotech’s Perspective

3:10 pm | Panel Discussion: What are the New Technologies to Enhance Our Understanding of Targeted Therapies?

Mallika Singh
VP, Translational Research
REVOLUTION Medicines

Day Two

Thursday 13th December 2018

2:40 pm | How Can We Increase Model Utility for Combination Therapy?

Paul Hallenbeck
Founder, President & CSO
Seneca Therapeutics

Dr. Hallenbeck is the Founder, President and Chief Scientific Officer. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immuno-therapeutics R&D. As the sole founder of Neotropix, he raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed several Phase I/II clinical trials, establishing an excellent safety record & compelling evidence of efficacy.

Day Two

Thursday 13th December 2018

3:10 pm | Panel Discussion: What are the New Technologies to Enhance Our Understanding of Targeted Therapies?

Sunil Chada
SVP of R&D
Seneca Therapeutics

Sunil Chada, Ph,D is the Vice President of Research and Development  Dr. Chada's drug development expertise includes antibodies, cell and gene therapies and small molecules for oncology, genetic diseases and immunotherapy. He is an expert in translating product concepts into clinical trials: >15 INDs; >20 Phase I-III. Dr. Chada is an adjunct faculty member in the Department of Experimental Therapeutics at MD Anderson Cancer Center at the University of Texas. He is also a special advisor to the chief scientific officer of MDACC Moonshots Initiative.

Day Two

Thursday 13th December 2018

3:10 pm | Panel Discussion: What are the New Technologies to Enhance Our Understanding of Targeted Therapies?

Gerold Feuer
Consultant
Crown Bioscience

Dr. Gerold Feuer was Founder and Chief Scientific Officer of HuMurine Technologies, Inc. Dr. Feuer obtained his B.A. at U.C. Berkeley and his Ph.D. at U.C. Irvine. After post-doctoral studies at U.C.L.A. Medical Center on human retrovirus infections in humanized mice, Dr. Feuer spent 18 years as a professor in the Department of Microbiology and Immunology at SUNY Upstate Medical University, Syracuse, where he established and served as the Director of SUNY UMU’s Center for Humanized SCID Mouse Models. Humurine was founded in 2008 as a SUNY- academic spinoff company, and HuMurine laboratory operations relocated adjacent to the U.C. Davis Medical Center and Institute for Regenerative Cures in Sacramento, CA, in 2011. Dr. Feuer retired from SUNY UMU in 2015 to return to California and to run HuMurine full-time. Dr. Feuer has published over 35 publications and has extensive background in the fields of human virology, immuno-oncology, gene therapies and human hematopoietic stem cells.

Day Two

Thursday 13th December 2018

3:45 pm | Chair’s Closing Remarks & End of PREDiCT Innovation Meeting

3:10 pm | Panel Discussion: What are the New Technologies to Enhance Our Understanding of Targeted Therapies?

1:30 pm | Chair’s Welcome

Georgina Cornish
Associate Principle Scientist, Cell Therapy Safety
AstraZeneca

Georgina is the Associate Principle Research Scientist in the Cell Therapy Safety team at AstraZeneca overseeing in vivo toxicity models for the preclinical safety assessment of the CAR-T cell portfolio. Prior to joining AstraZeneca, Georgina took an industrial placement which she co-ordinated and ran large scale CAR T-cell efficacy studies in immunocompromised mice carrying solid tumour xenografts. Georgina has spent over 15 years studying immunity in health and disease, starting from the biochemical building blocks that translate environmental cues into immune cell function by utilising models of complex disease. During her PhD study in the early 2000’s, Georgina's research focus was on describing a novel cytokine driven regulation of CD8+ T-cell metabolism pivotal to memory T cell differentiation and migration. In subsequent postdoctoral years, she focused on the immuno-modulatory effects of specialised tissue microenvironments in the context of autoimmune inflammation, transplantation and the generation, maintenance and survival of effector T-cells in vivo.  

Day One

Thursday 13th December 2018

10:40 am | Roundtable Discussion: What Preclinical Models Provide a Platform to Assess Immunotherapy Toxicology?

Stephanie Casey Parks
Scientist
Amgen

Day One

Thursday 13th December 2018

10:10 am | Designing the Next IO Model to Enhance Translatability

Henry Li
Chief Scientific Officer
Crown Bioscience

Day Two

Thursday 13th December 2018

2:10 pm | Living Biobank of Matched In Vitro & In Vivo Patient-Derived Models for Drug Development & Biomarker Identification

Ludovic Bourre
Senior Director, Scientific Engagement
Crown Bioscience

Day One

Thursday 13th December 2018

10:40 am | Roundtable Discussion: What Preclinical Models Provide a Platform to Assess Immunotherapy Toxicology?

9:40 am | Advancing Immuno-Oncology Therapies: What are the Next Generation Syngeneic Models?

Rajendra Kumari
Global Head of Scientific Communication
Crown Bioscience

Day One

Thursday 13th December 2018

12:00 pm | Chair’s Closing Remarks & End of Day 1

9:00 am | Chair’s Welcome